A randomized, double-blind, placebo-parallel-controlled, multi-center clinical trial to evaluate the efficacy and safety of Compound Chuanxiong Tablets in the treatment of coronary heart disease with stable angina pectoris (syndrome of blood stasis in the heart vessel)

INTERVENTION: Experimental group:Compound Chuanxiong Tablets: 4 tablets each time, 3 times a day; to be taken after meals, with a treatment course of 8 weeks.;Control group:Simulant of Compound Chuanxiong Tablets, 4 tablets each time, 3 times a day; to be taken after meals, with a treatment course of 8 weeks.; CONDITION: Stable angina pectoris of coronary heart disease (syndrome of blood stasis in the heart vessel) PRIMARY OUTCOME: The change in the total score of the Seattle Angina Questionnaire after 8 weeks of treatment compared with the baseline value; SECONDARY OUTCOME: The change in the total score of the Seattle Angina Questionnaire after 4 weeks of treatment compared with the baseline value;The changes in scores of each dimension of the Seattle Angina Questionnaire compared with the baseline values after 4 and 8 weeks of treatment;The withdrawal rate of nitroglycerin tablets after 4 and 8 weeks of treatment;The rate of patients whose TCM syndrome scores decreased by >=30% compared with the baseline scores after 8 weeks of treatment;The changes in the Short Form 36 Health Survey (SF‐36) scores compared with the baseline values after 4 and 8 weeks of treatment;Treadmill exercise electrocardiogram test1. The change in total exercise time after 8 weeks of treatment compared with the baseline value; 2. The change in Duke score after 8 weeks of treatment compared with the baseline value; INCLUSION CRITERIA: 1. Meeting the diagnostic criteria for stable angina pectoris of coronary heart disease in Western medicine; 2. Meeting the diagnostic criteria for the syndrome of heart blood stasis in traditional Chinese medicine; 3. Having angina pectoris symptoms, along with at least one of the following pieces of evidence for diagnosing coronary heart disease: a. A clear history of myocardial infarction in the past; b. Having undergone coronary revascularization therapy; c. Coronary angiography or coronary CTA examination indicating that at least one coronary artery has stenosis with a lumen stenosis of >=50%; 4. Patients with stable angina pectoris of coronary heart disease classified as Grade I ‐ III; 5. Those who, during the treadmill exercise test conducted at screening, show positive indicators within 3 ‐ 12 minutes after the start of exercise (Note: Male subjects evaluated by the treadmill exercise test need to meet this criterion during the screening period);